Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, Health Canada and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... -- Research and Markets  has announced the addition of the ... report to their offering. This report analyzes ... Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided for ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... Microfluidic Systems (MFSI),along with its manufacturing ... invited to attend the U.S. House of,Representatives ... and Responding to Bioterrorism. MFSI will be ... The purpose,of the fair is to educate ...
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... included an explanatory,paragraph in their opinion on the ... Report on Form 10-K for the year ended,December ... continue as a going,concern. The Company discusses this ...
... today,announced it has secured $20 million in venture ... includes Silicon Valley Bank,and Comerica Bank. Aerovance drew ... The remaining $10 million is available upon the ... interest and enthusiasm in Aerovance,and our clinical programs," ...
Cached Biology Technology:Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification 2
(Date:8/20/2014)... WORCESTER, MA Using population-based screening outcomes of approximately ... states, including four researchers at the University of Massachusetts ... combined immunodeficiency (SCID) can be successfully implemented across public ... programs published in the Aug. 20 issue of the ... JAMA ) showed the rate of SCID in newborns ...
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... plastic bags could one day be made out of ... are now reporting. The novel process they developed and ... its agricultural and plastic waste problems, appear in the ... S. Bayer and colleagues at the Italian Institute of ... In 2012, its production reached 288 million tons worldwide, ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... be processed unconsciously when the area of the brain ... down, according to research at Rice University in Houston. ... in the Proceedings of the National Academy of Sciences' ... than one pathway along which visual information can be ...
... have identified some of the key factors that prevent ... (MS), complications of premature birth, and other diseases and ... nervous system fails to repair itself and suggest ways ... be reversed. The research is published in the August ...
... an alien if you encountered it on the street tomorrow? ... rather was created in a laboratory right here on Earth ... Peter Ward has the beginnings of an answer. In a ... expanded "tree of life," or biological classification system, to account ...
Cached Biology News:Out of sight, out of mind? Not necessarily 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 3OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 4New book expands biological classifications to account for 'alien' life 2New book expands biological classifications to account for 'alien' life 3
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... Bio-Beads SM-2 adsorbents are macroporous polystyrene ... a high surface area for adsorbing organics ... aqueous solutions. The beads are useful for ... active agents; for example, the removal of ...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
... Phosphate Phosphatase 2 (LPP2) ... aqueous solution Solution ... containing 0.08% sodium azide. ... the human LPP2 protein. ...
Biology Products: